Immunotherapy in Patient With Poor General Condition

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-09-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancernsclccell lungsmall cellnon small
  Phrases that lowered it: arthritisrheumatoidaminotransferaseinflammatoryefficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 2 (raises risk) · Design
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 75 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 23.4% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 92.6% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 4734 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer NCT03030131 · started 2017 · scored riskier than 96% of active trials terminated
• Atezolizumab Immunotherapy in Patients With Advanced NSCLC NCT03102242 · started 2017 · scored riskier than 80% of active trials completed
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer NCT02250326 · started 2015 · scored riskier than 94% of active trials completed
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC NCT04163432 · started 2020 · scored riskier than 89% of active trials terminated
• Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC NCT04081688 · started 2019 · scored riskier than 94% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.